Boston Scientific Corporation $BSX Shares Sold by O Brien Greene & Co. Inc

O Brien Greene & Co. Inc lessened its stake in Boston Scientific Corporation (NYSE:BSX) by 93.2% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 6,820 shares of the medical equipment provider’s stock after selling 92,758 shares during the period. O Brien Greene & Co. Inc’s holdings in Boston Scientific were worth $298,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Avantax Planning Partners Inc. lifted its stake in Boston Scientific by 4.0% during the first quarter. Avantax Planning Partners Inc. now owns 5,242 shares of the medical equipment provider’s stock worth $329,000 after purchasing an additional 201 shares in the last quarter. Natural Investments LLC grew its stake in shares of Boston Scientific by 1.3% in the second quarter. Natural Investments LLC now owns 16,067 shares of the medical equipment provider’s stock valued at $685,000 after buying an additional 206 shares in the last quarter. 180 Wealth Advisors LLC grew its stake in shares of Boston Scientific by 3.6% in the first quarter. 180 Wealth Advisors LLC now owns 6,468 shares of the medical equipment provider’s stock valued at $406,000 after buying an additional 223 shares in the last quarter. MGO One Seven LLC raised its holdings in shares of Boston Scientific by 1.9% in the 3rd quarter. MGO One Seven LLC now owns 14,061 shares of the medical equipment provider’s stock valued at $614,000 after buying an additional 260 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich raised its holdings in shares of Boston Scientific by 1.4% in the 3rd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 19,918 shares of the medical equipment provider’s stock valued at $870,000 after buying an additional 268 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 1.5%

Boston Scientific stock opened at $44.67 on Wednesday. The firm has a market capitalization of $64.74 billion, a P/E ratio of 18.93, a P/E/G ratio of 1.30 and a beta of 0.60. The company has a current ratio of 1.36, a quick ratio of 0.81 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a twelve month low of $39.57 and a twelve month high of $105.65. The stock’s fifty day simple moving average is $44.19 and its 200-day simple moving average is $55.23.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, hitting analysts’ consensus estimates of $0.73. Boston Scientific had a return on equity of 18.61% and a net margin of 16.62%. The business had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. During the same period in the previous year, the company posted $0.75 earnings per share. The business’s revenue for the quarter was up 1.4% on a year-over-year basis. As a group, equities analysts expect that Boston Scientific Corporation will post 3.17 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BSX has been the topic of several research reports. JPMorgan Chase & Co. lowered Boston Scientific from an “overweight” rating to a “neutral” rating and set a $46.00 target price on the stock. in a research note on Wednesday, October 28th. Argus downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, July 31st. Royal Bank Of Canada cut their price target on shares of Boston Scientific from $70.00 to $52.00 and set an “outperform” rating on the stock in a research note on Thursday, October 29th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Boston Scientific in a research note on Friday, October 2nd. Finally, The Goldman Sachs Group reduced their price target on shares of Boston Scientific from $71.00 to $57.00 and set a “buy” rating on the stock in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $61.43.

Boston Scientific Profile

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.